| Title |
Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma
|
|---|---|
| Published in |
Journal of Neuro-Oncology, August 2008
|
| DOI | 10.1007/s11060-008-9662-x |
| Pubmed ID | |
| Authors |
Johannes E. A. Wolff, Christof Kramm, Rolf-Dieter Kortmann, Torsten Pietsch, Stefan Rutkowski, Norbert Jorch, Astrid Gnekow, Pablo Hernáiz Driever |
| Abstract |
Valproic acid (VPA) inhibits histone deacetylase and has been reported to induce apoptosis in glioma. We report 44 heavily pretreated pediatric patients with high-grade glioma or diffuse intrinsic pontine glioma who received VPA as oral continues maintenance treatment with individual dose adaptation. The tumor status when starting the drug was: no measurable disease in 12, measurable but stable disease in 12, and measurable progressive disease in 22 patients. Average trough blood levels of VPA were 99 mg/l. The most frequent complaint was somnolence (three patients), but no severe toxicity was reported. One relapse patient responded, early progression of disease was observed in three frontline patients and in six relapsed patients. Median overall survival duration for all patients was 1.33 years, with large differences between first-line (5-year overall survival, 44%) and relapse therapy (5-year overall survival, 14%). This shows that valproate is safe in this patient population. The moderate tumor efficacy encourages studying the drug further as an element of multi-agent protocols. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 4% |
| Brazil | 1 | 4% |
| Unknown | 22 | 92% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 42% |
| Student > Postgraduate | 4 | 17% |
| Student > Ph. D. Student | 2 | 8% |
| Student > Doctoral Student | 1 | 4% |
| Student > Bachelor | 1 | 4% |
| Other | 4 | 17% |
| Unknown | 2 | 8% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 42% |
| Agricultural and Biological Sciences | 6 | 25% |
| Biochemistry, Genetics and Molecular Biology | 2 | 8% |
| Psychology | 2 | 8% |
| Neuroscience | 1 | 4% |
| Other | 0 | 0% |
| Unknown | 3 | 13% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 May 2012.
All research outputs
#20,736,211
of 25,473,687 outputs
Outputs from Journal of Neuro-Oncology
#2,542
of 3,260 outputs
Outputs of similar age
#91,270
of 98,672 outputs
Outputs of similar age from Journal of Neuro-Oncology
#14
of 14 outputs
Altmetric has tracked 25,473,687 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,260 research outputs from this source. They receive a mean Attention Score of 4.4. This one is in the 11th percentile – i.e., 11% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 98,672 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 3rd percentile – i.e., 3% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.